RESEARCH ARTICLE

HIV-1 competition experiments in humanized mice show that APOBEC3H imposes selective pressure and promotes virus adaptation

Yusuke Nakano¹, Naoko Misawa¹, Guillermo Juarez-Fernandez¹, Miyu Moriwaki¹,², Shinji Nakaoka³,⁴, Takaaki Funo⁵, Eri Yamada¹, Andrew Soper¹, Rokusuke Yoshikawa¹*, Diako Ebrahimi⁶,⁷,⁸,⁹, Yuuya Tachiki¹,⁵,¹⁰, Shingo Iwami⁴,⁵,¹⁰, Reuben S. Harris⁷,⁸,⁹,¹¹, Yoshio Koyanagi¹, Kei Sato¹,¹⁰*

¹ Laboratory of Systems Virology, Department of Biosystems Science, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan, ² Graduate School of Biostudies, Kyoto University, Kyoto, Japan, ³ Institute of Industrial Sciences, The University of Tokyo, Meguro-ku, Tokyo, Japan, ⁴ PRESTO, Japan Science and Technology Agency, Kawaguchi, Saitama, Japan, ⁵ Mathematical Biology Laboratory, Department of Biology, Faculty of Sciences, Kyushu University, Fukuoka, Japan, ⁶ Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, Minnesota, United States of America, ⁷ Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States of America, ⁸ Institute for Molecular Virology, University of Minnesota, Minneapolis, Minnesota, United States of America, ⁹ Center for Genome Engineering, University of Minnesota, Minneapolis, Minnesota, United States of America, ¹⁰ CREST, Japan Science and Technology Agency, Kawaguchi, Saitama, Japan, ¹¹ Howard Hughes Medical Institute, University of Minnesota, Minneapolis, Minnesota, United States of America

* Current address: Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan
* ksato@virus.kyoto-u.ac.jp

Abstract

APOBEC3 (A3) family proteins are DNA cytosine deaminases recognized for contributing to HIV-1 restriction and mutation. Prior studies have demonstrated that A3D, A3F, and A3G enzymes elicit a robust anti-HIV-1 effect in cell cultures and in humanized mouse models. Human A3H is polymorphic and can be categorized into three phenotypes: stable, intermediate, and unstable. However, the anti-viral effect of endogenous A3H in vivo has yet to be examined. Here we utilize a hematopoietic stem cell-transplanted humanized mouse model and demonstrate that stable A3H robustly affects HIV-1 fitness in vivo. In contrast, the selection pressure mediated by intermediate A3H is relaxed. Intriguingly, viral genomic RNA sequencing revealed that HIV-1 frequently adapts to better counteract stable A3H during replication in humanized mice. Molecular phylogenetic analyses and mathematical modeling suggest that stable A3H may be a critical factor in human-to-human viral transmission. Taken together, this study provides evidence that stable variants of A3H impose selective pressure on HIV-1.

Author summary

Human APOBEC3 family proteins are known as intrinsic defenses against HIV-1, whereas HIV-1 Vif counteracts APOBEC3-mediated anti-viral action. Using a hematopoietic stem
introduction

Apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3 (APOBEC3; A3) enzymes are cellular single-stranded DNA cytosine deaminases that are specifically encoded in mammals [1,2]. Rodents including mice (Mus musculus) have a single A3 gene, while primates including humans (Homo sapiens), chimpanzees (Pan troglodytes) and Old World monkeys have seven A3 paralogous genes (A3A, A3B, A3C, A3D, A3F, A3G and A3H). Gene duplication is a hallmark of the genes that are under evolutionary selective pressures [3], and indeed, the seven primate A3 genes have been positively selected during evolution [4]. These observations suggest that primate A3 proteins play crucial roles in primates including humans. Human A3G was discovered first and was shown to be capable of restricting the replication of human immunodeficiency virus type 1 (HIV-1) in an in vitro cell culture system [5]. Subsequent investigations revealed that several human A3 family proteins exhibit the ability to reduce HIV-1 infectivity [2,6–8]. Moreover, previous studies including ours have demonstrated that HIV-1 encodes a protein named viral infectivity factor (Vif). Vif orchestrates cellular ubiquitin ligase complex and degrades anti-viral A3 proteins via ubiquitin/proteasome-dependent pathway in infected cells [2,13].

In addition to A3D, A3F and A3G, human A3H is known as a potent restriction factor against HIV-1. Human A3H is polymorphic and has seven haplotypes [14,15]. Three of them, called haplotypes II, V, and VII, produce stably expressed enzymes that exhibit anti-HIV-1 activity in model cell culture experiments as well as primary T lymphocytes ex vivo [14–16]. In contrast, the other three haplotypes (III, IV, and VI) do not exhibit detectable protein expression [14–16]. Additionally, our recent study has demonstrated that A3H haplotype I (A3H-I) has intermediate stability and clear enzymatic activity [17] (Fig 1A). Importantly, the frequency of each haplotype differs among human population, with a higher frequency of stable A3H in the African-descendant population [14,15]. Furthermore, it is more intriguing that the Vif proteins of certain HIV-1 strains are unable to counteract stable A3H haplotypes, and the ability of Vif to antagonize stable A3H is determined by at least two residues at positions 39 and 48 (Fig 1B) [18–20]. These observations suggest that both the A3H-mediated anti-viral effect and the antagonistic ability of Vif against A3H are co-mingled in the human population, in contrast to the functional relationships between Vif and A3D, A3F and A3G, which appear much less variable. However, the robustness of the effects of stable/intermediate A3H haplotypes on viral replication at an individual scale and a population scale remains unclear, and the
Fig 1. Dynamics of hyper/hypo HIV-1 infection in stable A3H humanized mice. (A) A schematic of the A3H gene locus and the 5 polymorphisms in A3H exons 2, 3, and 4 (indicated by red vertical lines) that combine to produce 7 different haplotypes. Red arrowheads with horizontal broken lines indicate the region amplified by genotyping PCR. In the bottom panel, the 7 different A3H haplotypes based on observed protein stability or instability in previous studies [14,15,20] are summarized. (B) (top) A schematic of the Vif protein encoded by HIV-1 used in this study. This panel shows the amino acid differences responsible for the degradation of stable A3H. (bottom) TZM-bl assay. The infectivity of released virions was determined by using TZM-bl cells.
dynamics by which HIV-1 may circumvent and/or counteract the anti-viral effect of stable A3H is yet to be addressed.

Here we use an HSC-transplanted humanized mouse model to demonstrate that stable A3H, but not intermediate A3H, which is endogenously expressed in human CD4+ T cells, is a bona fide restriction factor capable of controlling HIV-1 replication in vivo. In addition, we reveal that HIV-1 Vif readily acquires the ability to counteract stable A3H during viral expansion in vivo. Additionally, we use molecular phylogenetic analysis and mathematical modeling to further address the impact of stable A3H on HIV-1 epidemics. Our analyses suggest that stable A3H may control HIV-1 dissemination in both intra- and inter-individual scales.

**Results**

**Endogenous A3H exploits robust anti-viral effect in vivo**

To address the impact of endogenous A3H haplotypes (Fig 1A) on HIV-1 replication in vivo, two derivatives of the replication-competent CCR5-tropic HIV-1 strain NLCSFV3 [21] were made with differing A3H haplotype II (A3H-II) neutralization capabilities [20]. One virus encodes a Vif protein that is able to counteract stable A3H ("hyper Vif"), while the other encodes a Vif protein that does not ("hypo Vif") (Fig 1B) [20]. Importantly, previous reports demonstrated that the Vif’s ability to degrade stable A3H is determined by the two amino acid residues at positions 39 and 48 (Fig 1B) [18–20]. Consistent with a prior study [20], hyper HIV-1 fully counteracted the anti-viral activity mediated by A3H-II, whereas hypo Vif was not able to counteract A3H-II (Fig 1B). In the absence of A3H-II, the infectivity of both of these HIV-1 molecular clones is similar (Fig 1B).

To investigate the impact of endogenous A3H on HIV-1 replication in vivo, a series of hyper versus hypo Vif competition experiments was conducted in humanized mice reconstituted with stable A3H-expressing HSCs. The first experiment used eight humanized mice, which were heterozygous for stable A3H haplotypes (S1 Table); two out of the eight had blood cell compartments reconstituted with haplotypes III and V cells, and the other six mice expressed haplotypes I and II (S1 Table). Next, these eight mice were intraperitoneally co-inoculated with equal amounts of hyper and hypo viruses (1,500 TCID<sub>50</sub> each; Fig 1C), and the amount of viral RNA in the plasma and the level of human CD4+ T cells in the peripheral blood (PB) were routinely analyzed for 6 weeks post-infection (wpi). HIV-1 efficiently expanded in the humanized mice, as observed in our previous studies [11,12,22–24], and the level of peripheral CD4+ T cells was significantly reduced compared to mock-infected mice (Fig 1D). At 6 wpi, viral RNA was extracted from the plasma of infected mice and the sequences of the vif gene were analyzed. As anticipated, hyper vif and its derivatives were able
to outcompete hypo vif virus in mice expressing stable A3H (73.1% ± 7.7% [286/391] in Fig 1E; see also S2 Table). However, hypo vif-related sequences were the majority in infected mouse no. 5 and were still present at significant levels in all animals (no. 5, 67.3% [35/52] to no. 1, 7.9% [3/38]; Fig 1E & S2 Table). These results raised the possibility that these hypo vif viruses may have adapted in vivo and gained a better ability to counteract stable A3H during viral replication. To address this idea, we subcloned the 13 hypo vif-related open reading frames (ORFs) into the expression plasmid and evaluated their anti-stable A3H activity using in vitro cell culture system. As shown in Fig 1F, adapted Vif proteins with V39F/N48H (26 clones from 4 mice), V39F/N48H/D113N (1 clone from 1 mouse) and V39F/N48H/L148S (1 clone from 1 mouse) mutations, degraded A3H-II and impaired the A3H-II packaging into the released viral particles. Additionally, the HIV-1 restriction capacity of A3H-II was significantly counteracted by these 3 adapted hypo Vif derivatives as evidenced by hyper Vif levels of infectivity (Fig 1G). We verified that these 3 hypo Vif derivatives as well as parental hypo Vif were active in counteracting other HIV-1 relevant A3s such as A3D, A3F and A3G (S1 Fig). Together, the sequencing results and the tests of the functionality of the adapted hypo Vif proteins indicated that 80.3% ± 4.8% (314/391) of the vif sequences in the plasma of infected stable A3H mice are able to counteract stable A3H (Fig 1E–1G & S2 Table). These findings indicate that the ability to antagonize stable A3H is required for efficient HIV-1 replication in humanized mice.

Intermediate A3H-I does not elicit selective pressure on HIV-1 replication in humanized mice

We next investigated whether HIV-1 undergoes selection as a result of pressure from A3H-I in vivo. Six humanized mice were reconstituted with HSCs from three individual donors. Five out of the six mice were homozygotes for A3H-I and one mouse was heterozygous for A3H haplotypes I and VI (S1 Table). These six mice were co-inoculated with hyper and hypo HIV-1s (Fig 2A). All mice exhibited a high level of viremia and a declined level of peripheral CD4+ T cells (Fig 2B). We then analyzed the vif sequences in the plasma of these six infected mice at 6 wpi. In contrast to the observations from animals with at least one copy of stable A3H (hap II or V; Fig 1E), the proportion of hyper/hypo vif sequences varied in each infected mouse, and no obvious replication biases were observed (Fig 2C & S3 Table). On average, the percentage of hyper and hypo vif-derived sequence were similar, 46.5% ± 13.7% (127/273) and 53.5% ± 13.7% (146/273), respectively (S4 Table).

To assess whether A3H genotype affects the expression level of other HIV-1 relevant A3 genes, we analyzed the expression levels of A3D, A3F and A3G in the splenic CD4+ T cells of humanized mice. Consistent with our previous studies with primary CD4+ T cells ex vivo and with humanized mice [24,25], the mRNA expression levels of these A3 genes in HIV-1-infected mice were significantly higher than those in mock-infected mice (S2A Fig). The expression levels of these A3 genes were comparable between the humanized mice expressing stable A3H and intermediate A3H (S2B Fig), indicating that the A3H genotype is not associated with the expression levels of other HIV-1 relevant A3 genes.

In addition to A3H, single nucleotide variants (SNVs) in human A3G [26–28], A3F [29,30] and A3D [31] have been reported. The variants of A3G [28] and A3D [31] are degraded efficiently by HIV-1 Vif and are therefore unlikely to play significant roles in vivo. In contrast, An et al. have recently reported that an SNV of A3F, V231I, confers partial resistance to Vif-mediated degradation by certain strains of HIV-1 [30]. To address the possibility that A3F V231I mutant affects viral growth and the sensitivity to hyper/hypo HIV-1, we assessed the genomic sequences of A3F. However, this A3F SNV was not detected in the human cells used in our
studies (data not shown). Altogether, these findings suggest that no specific selective pressure is elicited against either hyper or hypo HIV-1 in intermediate A3H humanized mice and that virus expansion is occurring in a stochastic manner.

The ability to counteract stable A3H is acquired de novo during viral replication in vivo

Co-infection studies revealed that hyper Vif HIV-1 dominates over hypo Vif virus in animals humanized with stable A3H expressing cells (Fig 1). These observations suggest that the stable A3H protein, which is expressed endogenously in human CD4+ T cells, exhibits a robust anti-viral effect and impairs the expansion of the viruses without full A3H counteraction abilities (i.e., V39 hypo Vif). We used three HIV-1 strains, NLCSFV3, JRCSF and AD8 to demonstrate that the Vif proteins of these viruses are unable to antagonize A3H-II (S3 Fig). We then inoculated these viruses into 50 humanized mice reconstructed from 16 HSC donors (Fig 3A). The genotyping PCR revealed that 13 out of the 16 HSC donors encode A3H-I, and 3 donors possessed one stable A3H allele (S5 Table). Based on A3H haplotypes, these infected mice were classified into two groups, intermediate A3H (n = 37) and stable A3H (n = 13), and the level of peak viral load in each group was compared. As shown in Fig 3B, surprisingly, the peak viral load was comparable between intermediate A3H mice and stable A3H mice (P = 0.92 by Mann-Whitney U test). Because certain hypo vif derivatives acquired anti-stable A3H activity in the stable A3H mice co-inoculated with hyper/hypo HIV-1 (Fig 1E–1G), we hypothesized that these viruses acquired de novo resistance to stable A3H in vivo (strains NLCSFV3, JRCSF, or AD8; Fig 3B). To test this hypothesis, we analyzed the vif sequences in the plasma of the 4 stable A3H mice infected with HIV-1 (strain NLCSFV3) at 6 wpi. Notably, some Vif sequences were commonly detected in the 4 stable A3H mice infected with NLCSFV3 (Fig 3C; the raw
data and mutation matrix are shown in S4 Fig). To investigate whether these mutant variants acquired anti-stable A3H activity de novo, we prepared the expression plasmids of these Vif derivatives and conducted in vitro experiments using our cell culture system. As shown in Fig 3D & 3E, we detected 2 Vif variants, N48H and V13I/N48H/GD60-63 EKGE, that are able to antagonize A3H-II at the level observed for hyper Vif. In summary, 59.7% ± 5.1% (145/243) of the vif sequences in the plasma acquired the ability to counteract stable A3H (S6 Table), but such mutants were not detected in the intermediate A3H mice infected, solely, with NLCSFV3 (S5 Fig & S7 Table). Taken together, these findings suggest that the ability of HIV-1 Vif to antagonize stable A3H is acquired de novo during viral expansion in vivo.
Up-regulation of endogenous A3H expression by HIV-1 infection in vivo

We previously reported that endogenous A3H mRNA expression levels in primary human CD4+ T cells are significantly lower than those of anti-viral A3 genes such as A3D, A3F, and A3G, and that activation and/or infection stimuli induces higher A3H expression [25,32]. In agreement with these prior works, the activation stimuli driven by anti-CD3/CD28 antibodies induced the expression of CD25, a marker of activated human CD4+ T cells (S6A Fig), and also A3H mRNA expression levels (P = 0.010 by paired t test, S6B Fig). However, it should be noted that human CD4+ T cells in humanized mice [12] and human PB [33] are less activated (S6C Fig) and in a quiescent state. In this regard, previous studies reported that HIV-1 infection induces the activation of CD4+ T cells of infected individuals [34,35]. Therefore, we hypothesized that HIV-1 infection induced CD4+ T-cell activation and augmented A3H expression in humanized mice, and this resulted in robust anti-viral effect by endogenous A3H (Figs 1 & 3). To investigate the immune activation status in detail, we performed RNA sequencing (RNA-seq). Human mononuclear cells (MNCs) were isolated from the spleen of 4 HIV-1-infected mice and 4 mock-infected mice at 6 wpi, and RNA-seq analyses were conducted. As shown in Fig 4A, 93 genes were significantly up-regulated by HIV-1 infection, whereas 16 genes were down-regulated. Parametric gene set enrichment analysis (GSEA)
revealed that the genes associated with T-cell/lymphocyte activation, inflammatory response, and positive regulation of T cell activation were significantly up-regulated in the human MNCs of HIV-1-infected mice (Fig 4B; the GESA result is listed in S8 Table). In addition, various interferon-stimulated genes such as RSAD2 (encoding Viperin), DDX58 (encoding RIG-I), EIF2AK2 (encoding PKR), MX1, ISG15, MOV10 and BST2 (encoding tetherin) were up-regulated in HIV-1-infected mice (Fig 4A). As observed in infected patients [34,35], our findings suggest that HIV-1 infection triggers immune activation in humanized mouse model.

We then addressed the possibility that the immune activation caused by HIV-1 infection (Fig 4A & 4B) leads to the up-regulation of A3H in humanized mice. As shown in Fig 4C, the proportion of the splenic CD4+ T cells (CD3+ CD8− cells) of infected mice was significantly lower than that of uninfected mice, and particularly, CD25+ activated CD4+ T cells were severely depleted by HIV-1 infection (P = 0.0039 versus mock infection). Consistent with our previous findings [12], HIV-1 infection led to the severe depletion of activated CD4+ T cells in humanized mice.

Next, we sorted the fractions of non-activated CD4+ T cells (CD45+ CD3+ CD8− CD25− cells) and activated CD4+ T cells (CD45+ CD3+ CD8− CD25+ cells) of mock-infected mice (S7 Fig) and analyzed the mRNA expression level of A3H in each population by real-time RT-PCR. In mock-infected mice, A3H expression in the activated CD4+ T cells was significantly higher than that in non-activated cells (P = 0.0090 by Mann-Whitney U test; Fig 4D). This finding further suggests that the CD4+ T-cell activation augments A3H expression, as observed in in vitro experiments (S6B Fig) and in our previous reports [25,32]. Because CD25+ CD4+ T cells were severely depleted in infected mice (Fig 4C), we sorted only the fraction of CD25− CD4+ T cells (CD45+ CD3+ CD8− CD25− cells) of HIV-1-infected mice for real-time RT-PCR. Interestingly, the A3H expression level in the CD25− CD4+ T cells of HIV-1-infected humanized mice was significantly higher than that of CD25+ CD4+ T cells of uninfected mice (P = 0.0062 by Mann-Whitney U test; Fig 4D). Altogether, these findings suggest that the immune activation triggered by HIV-1 infection augments A3H expression in CD4+ T cells of infected humanized mice.

**A3H haplotype may influence HIV-1 spread in human population**

Finally, we addressed how hyper and hypo HIV-1 sequences circulate in the human population. The HIV-1 Vif sequences were obtained from the Los Alamos National Laboratory HIV-1 sequence database (https://www.hiv.lanl.gov/components/sequence/HIV/search/search.html). Fig 5A shows a phylogenetic tree of Vif sequences of HIV-1 group M (n = 2,976), which is a pandemic strain worldwide. The phylogenetic tree indicates that Vif sequences cluster based on subtype (Fig 5A). Interestingly, the sequences of hyper Vif (here we defined "hyper Vif" as a sequence that possesses F or Y at position 39 and H at position 48) scattered in this tree and did not form a unique cluster (Fig 5A). Additionally, the percentage of hyper Vif varied in each subtype (Fig 5B), suggesting that hyper and hypo Vif mutually swap in human population.

To evaluate the counteracting ability of HIV-1 clinical isolates (group M) against stable A3H, we used 15 infectious molecular clones (IMCs): 8 subtype B and 7 subtype C; 10 transmitted/founder (TF) viruses and 5 chronic control (CC) viruses. As shown in Fig 5C, the infectivity of the 3 IMCs (strains AD17, RHPA and MCST) was significantly suppressed by A3H-II with statistical differences, suggesting that these viruses have established new infection as TF viruses in individuals without anti-stable A3H activity. In contrast, other 12 IMCs overcame A3H-II-mediated restriction (Fig 5C), suggesting that these viruses exist in human population as hyper HIV-1. Importantly, the anti-stable A3H ability of these IMCs corresponded well to
Fig 5. Dynamics of hyper/hypo HIV-1 dissemination in human population. (A) A phylogenetic tree of Vif. The Vif sequences were extracted from HIV-1 sequence database (https://www.hiv.lanl.gov/components/sequence/HIV/search/search.html) and the phylogenetic tree was constructed as described in Materials and Methods. The branches of hyper Vif sequences (i.e., F or Y in position 39 and H in position 48) are indicated with pink. Each color surrounding the phylogenetic tree represents viral subtype (A1-K). Scale bar indicates 5.0 amino acid substitutions per site. (B) The percentage of hyper Vif sequences in each subtype and group. The sequences of HIV-1 Vif is classified into hyper and hypo Vif based on the amino acids positioned at 39 and 48 and the result is summarized. The numbers in parentheses represents the number of Vif sequences used. See also S10 Table. (C) TZM-bl assay. The IMCs (1,000 ng) were cotransfected either with or without Flag-tagged A3H-II expression plasmid (50 ng) into HEK293T cells. The infectivity of released virus was determined by using TZM-bl cells, and the percentage of the value of "no A3H-II" is shown. *P < 0.05 versus "hyper HIV-1" by Student's t test. The assay was performed in triplicate. The data represents average with SD. TF, transmitted/founder; CC, chronic control. See also S9 Table. (D) Distribution of hyper HIV-1 and individuals with stable A3H in the world. The percentages of hyper HIV-1 (pink, top) and stable A3H haplotype (green, bottom) in each region (Europe, Africa, Asia and North America; represented in bold) and country were obtained as described in Materials and Methods, and these two values are indicated by heatmap. The Vif amino acids at positions 39 and 48 are shown in logoplot, and the residues associated with hyper Vif (i.e., F or Y in position 39 and H in position 48) are represented in pink. Note that the information of the proportion of A3H haplotype is not available in Russia, Australia, Central America and South America. See also S11 Table. (E) Mathematical modeling of the dissemination of hyper HIV-1 in
the amino acid residues positioned at 39 and 48 (S9 Table). These findings suggest that anti-stable A3H ability is not a necessary requirement for certain viruses circulating within individuals.

We then assessed the anti-stable A3H ability of non-pandemic HIV-1 groups N, O, and P. As shown in Fig 5B, the proportion of hyper Vif sequences varied in each group. In particular, HIV-1 group O strains (n = 51) did not encode a hyper vif sequences. However, the cell-based experiments demonstrated that the IMCs of group O (strains BCF183 and RBF206) overcame A3H-II-mediated anti-viral effect (Fig 5C). The IMC of HIV-1 group P (strain RBF168) also counteracted A3H-II, while that of HIV-1 group N (strain DJO0131) did not (Fig 5C). Interestingly, in contrast to the results of HIV-1 group M, the anti-stable A3H ability of HIV-1 group O Vif was not governed by the two residues at positions 39 and 48 (S9 Table). These findings suggest that other residues than those positioned at 39 and 48 determine the ability of Vif proteins of HIV-1 group O to counteract stable A3H.

Furthermore, we assessed the correlation between the frequency of hyper HIV-1 and the proportion of the individuals harboring stable A3H haplotype worldwide. The HIV-1 Vif sequences were obtained from HIV-1 sequence database (S10 Table), and the information of A3H haplotype was obtained from the 1000 Genomes Project (http://www.internationalgenome.org) [36] (S11 Table). As shown in Fig 5A & 5B, the Vif sequences are highly diversified and the logoplot (S8 Fig) further indicated that the amino acids at position 39 and 48 were not highly conserved when compared to the YRHHY motif, which is essential for A3G degradation [24,37]. Additionally, consistent with previous reports [14,15,20], both the percentage of hyper Vif and the proportion of stable A3H haplotype were highest in Africa, particularly in Nigeria (Fig 5D & S12 Table), and these two parameters were correlated each other with statistical significance (Spearman’s \( r = 0.720, P = 0.017 \) by Spearman rank correlation test; S9 Fig). To further investigate the relationship between hyper HIV-1 and stable A3H haplotype, we conducted a mathematical simulation. As shown in Fig 5E, the frequency of hyper HIV-1 increased dependent on the proportion of the people harboring stable A3H haplotype. Taken together, our analyses at a human population level suggest that stable A3H elicits a selective pressure against HIV-1, and that HIV-1 overcomes stable A3H-mediated anti-viral immunity by acquiring the ability to counteract stable A3H.

**Discussion**

In this study, we used a humanized mouse model to show that HIV-1 infection induces immune activation and augments the expression of endogenous A3H in human CD4+ T cells (Fig 4). We also showed that the ability of HIV-1 Vif to counteract stable A3H-mediated anti-viral effect is crucial for efficient viral expansion in vivo when endogenous A3H is expressed stably (Figs 1 & 3). In contrast, the ability of HIV-1 Vif to counteract stable A3H is dispensable when stable A3H is absent in vivo (Fig 2). Furthermore, we addressed the significance of the stable A3H-mediated anti-viral effect on HIV-1 dissemination in human populations using molecular phylogenetic analysis and mathematical modeling. The occurrence of hyper Vif variants and stable A3H haplotypes correlates worldwide, suggesting that the ability of Vif to antagonize stable A3H was acquired during viral spread throughout the human population (Fig 5). These findings suggest that the A3H polymorphism influences HIV-1 dissemination at individual and population levels.
In the stable A3H humanized mice co-inoculated with hyper and hypo HIV-1 infectious clones, several hypo Vif viruses acquired V39F and N48H changes, which resulted in the gain-of-function to counteract A3H-II (Fig 1E–1G). Given that these two amino acids are identical to those in hyper Vif, the emergence of the hypo Vif derivatives, which can potently antagonize A3H-II in the hyper/hypo HIV-1 co-inoculated stable A3H mice (Fig 1), may be due to the recombination between hypo and hyper Vif sequences. However, the results shown in Fig 3 argue against this possibility. We demonstrated that some Vif sequences with the ability to antagonize stable A3H emerge during viral replication in the stable A3H mice within only 6 weeks. In contrast, in the intermediate A3H mice co-inoculated with hyper and hypo HIV-1 clones, the hyper or hypo Vif viruses expanded randomly with no evidence of selection on vif (Fig 2). These findings suggest that the stable A3H, which is endogenously expressed in CD4+ T cells, has a robust anti-viral activity in vivo and that it is feasible for Vif to acquire the counteracting ability against stable A3H de novo. We favor a model in which the starting hypo Vif virus is constrained evolutionarily, likely by needing to counteract A3D, A3F, and A3G, and that de novo (not recombination mediated) amino acid substitutions at positions 39 and 48 provide the most efficient route to optimize anti-A3H activity. Moreover, it is important to note that all the stable A3H humanized mice used in this study were heterozygous for A3H stability (S1 & S5 Tables). It appears that an allele of stable A3H is sufficient to induce a robust selective pressure against HIV-1.

In sharp contrast to the findings in the stable A3H mice co-inoculated with hyper and hypo HIV-1s (Fig 1), hyper HIV-1 was not commonly selected in the intermediate A3H mice co-inoculated with hyper and hypo HIV-1 clones (Fig 2). Also, de novo emergence of hyper Vif was not detected in the intermediate A3H mice infected with NLCSFV3 (S5 Fig). On the other hand, we recently showed that the intermediate A3H (A3H-I) is enzymatically active and contributes to breast and lung cancer mutagenesis despite being expressed at lower levels compared to its stable A3H counterpart [17]. These findings suggest that A3H-I, which is endogenously expressed in human CD4+ T cells, is not sufficient to impose selective pressure on HIV-1 replication in vivo.

Here we detected the emergence of Vif sequences that acquired the ability to antagonize stable A3H (Figs 1 & 3). In contrast, in the humanized mice infected with a vif-mutated HIV-1 (designated 4A HIV-1), which is sensitive to A3D and A3F, we have previously demonstrated that Vif sequences with the ability to antagonize A3D and A3F do not emerge [24]. We confirmed the absence of Vif revertants in the plasma of two 4A-HIV-1 infected mice infected at 6 wpi (S10 Fig). These observations suggest that HIV-1 is able to overcome the restriction mediated by stable A3H but not by A3D and A3F during viral replication in vivo. Two nonexclusive models may explain the observed differences. One possibility is that it might be more feasible for Vif to overcome stable A3H-mediated restriction than A3D/A3F because the anti-viral activity of endogenous stable A3H is lower than those of endogenous A3D and A3F. However, at least four previous studies have demonstrated that the anti-HIV-1 activity of stable A3H (haplotype II) is similar to that of A3F and is higher than that of A3D [18,19,25,38] and argue against this possibility. In addition, it should be noted that the endogenous expression levels of the respective A3 genes in primary human CD4+ T cells are different from each other. Indeed, Refsland et al. have revealed that endogenous expression levels of A3D and A3F mRNAs are higher than that of A3H in primary CD4+ T cells [32]. Another possibility is the number of amino acids responsible for A3 counteraction: only two amino acids at positions 39 and 48 are responsible for counteracting stable A3H [18–20], while there are four that are responsible for counteracting A3D and A3F (known as DRMR motif at position 14–17) [37,39].

The emergence of Vif revertants harboring the ability to counteract stable A3H is reminiscent of the observations that the sub-optimal drug concentrations facilitate the emergence of
drug-resistant viruses in infected patients [40,41]. In fact, it appears difficult for Vif to acquire the ability to counteract A3F and A3G de novo during viral replication in cell cultures [42,43] and a humanized mouse model [11,24]. In contrast, previous studies have successfully selected the viruses that acquired the ability to counteract stable A3H in the in vitro culture infection experiments using the human CD4+ T cell lines such as MT-4 cells [18] and SupT11 cells [20] that ectopically express A3H-II. Here we demonstrated that HIV-1 infection induces immune activation in humanized mice, as observed in infected individuals [34,35], and augments the expression of endogenous A3H in the human CD4+ T cells of infected mice (Fig 4). But still, the anti-HIV-1 activity of endogenous stable A3H is not sufficient to control viral expansion in vivo, and therefore, Vif may easily acquire the ability to counteract the restrictive activity of endogenous A3H.

Our findings in infected humanized mice revealed that hyper HIV-1 is predominantly selected in the mice expressing stable A3H (80.3% ± 4.8%; S2 Table), while the viruses replicated in the mice with intermediate A3H were selected stochastically (46.5% ± 13.7%; S4 Table). We also demonstrated the de novo emergence of hyper HIV-1 in the stable A3H mice infected with NLCSFV3 (59.7% ± 5.1%; S6 Table). Based on these findings and numerical parameters, we investigated the dynamic effect of A3H haplotypes on HIV-1 epidemic in the human population through molecular phylogenetic and mathematical modeling and revealed that the occurrence of hyper Vif and stable A3H variants are correlated positively in the human population (Fig 5). This suggests that stable A3H may not just provide an intrinsic immunity at the level of individual patients, as elaborated here in humanized mice, but it may also function to control the dissemination of hypo HIV-1 isolates in the human population [44,45].

Materials and methods

Ethics statement

All procedures including animal studies were conducted following the guidelines for the Care and Use of Laboratory Animals of the Ministry of Education, Culture, Sports, Science and Technology, Japan. The authors received approval from the Institutional Animal Care and Use Committees (IACUC)/ethics committee of the institutional review board of Kyoto University (protocol number D15-08). All protocols involving human subjects were reviewed and approved by the Kyoto University institutional review board. All human subjects were provided written informed consent from adults.

Humanized mice

NOG mice (NOD/SCID/Il2r KO mice) [46] were obtained from the Central Institute for Experimental Animals (Kawasaki, Kanagawa, Japan). The mice were maintained under specific-pathogen-free conditions and were handled in accordance with the regulation of the IACUC/ethics committee of Kyoto University. Human CD34+ hematopoietic stem cells (HSCs) were isolated from human fetal liver as previously described [47]. The humanized mouse model (NOG-hCD34 mouse) was constructed as previously described [11,22,23,48–50]. In the experiments shown in Figs 1 & 2, 14 newborn (aged 0 to 2 days) NOG mice from 7 litters were irradiated with X-ray (10 cGy per mouse) using an RX-650 X-ray cabinet system (Faxitron X-ray Corporation) and were then intrahepatically injected with the human fetal liver-derived CD34+ cells (1.0 × 10⁶ to 2.3 × 10⁵ cells; 5 donors). A list of the humanized mice used in this study is summarized in S1 Table. In the experiments shown in Fig 3, the 35 NOG-hCD34 mice infected with HIV-1 were used in our previous studies [12,23,24] (Fig 3) and the
15 NOG-hCD34 mice were newly infected with HIV-1. These humanized mice were constructed using 16 independent HSC donors with 29 NOG litters (summarized in S5 Table).

**Cell culture**

HEK293T cells (a human embryonic kidney 293 T cell line; ATCC CRL-3216) and TZM-bl cells (obtained through the NIH AIDS Research and Reference Reagent Program) [51] were maintained in Dulbecco’s modified Eagle’s medium (Sigma) containing FCS and antibiotics. Human peripheral CD4\(^+\) T cells were isolated from human CD4\(^+\) T cell isolation kit (Miltenyi) according to the manufacturer’s protocol. These cells were activated with anti-CD3/anti-CD28 dynabeads (Thermo Fisher Scientific) and maintained in RPMI1640 (Sigma) containing FCS and antibiotics with human interleukin-2 (100 U/ml) as previously described [23].

**Virus preparation and infection**

To construct the IMCs of hyper HIV-1 and hypo HIV-1 derivatives (based on a CCR5-tropic strain NLCSFV3 [21]), the hyper and hypo Vif variants of the HIVIIIB A200C proviral constructs [20] were digested with AgeI and EcoRI, then the resultant DNA fragment was inserted into the AgeI-EcoRI site of pNLCSFV3 [21]. The IMCs of HIV-1 strains JRCSF [52] and AD8 [53] were also used. The two vif-mutated derivatives based on pNLCSFV3, vif-deleted virus (pNLCSFV3Δvif) and DRMR/AAAA-mutated virus (4A HIV-1), are constructed in our previous study [11,24]. The IMCs of transmitted/founder (TF) and chronic control (CC) viruses as well as those of HIV-1 groups N (strain DJO0131), O (strains BCF183 and RBF206) and P (strain RBF168) (Fig 5C) were obtained kindly provided by Drs. Beatrice H. Hahn (University of Pennsylvania, USA) and Frank Kirchhoff (Ulm University Medical Center, Germany). To prepare virus solutions of hyper and hypo HIV-1s, 30 \(\mu\)g of each IMC was transfected into HEK293T cells according to calcium-phosphate method as previously described [11,12,23,24]. At 48 h posttransfection, the culture supernatant was harvested, centrifuged, and then filtered through a 0.45-\(\mu\)m filter (Millipore) to obtain the virus solution. The amount of viral particles was quantified using an HIV-1 p24 (Gag) antigen ELISA kit (Zeptometrix). Virus solutions of hyper and hypo HIV-1 clones (containing 2.5 ng of Gag antigen each) were intraperitoneally co-inoculated into NOG-hCD34 mice. RPMI 1640 was used for mock infection.

**PB collection, MNC isolation and quantification of HIV-1 RNA in plasma**

PB and plasma were routinely collected as previously described [11,12,22–24]. The mice were euthanized at 6 wpi with anesthesia and the spleen was crushed, rubbed, and suspended as previously described [11,12,22–24]. To obtain splenic human MNCs, the splenic cell suspension was separated using Ficoll-Paque (Pharmacia) as previously described [11,12,22–24]. The amount of HIV-1 RNA in 50 \(\mu\)l plasma was quantified by Bio Medical Laboratories, Inc. (the detection limit of HIV-1 RNA is 800 copies/ml).

**Genotyping PCR**

In the experiments shown in Figs 1 & 2, genomic DNA was extracted from the PB of NOG-hCD34 mice using a DNeasy Blood & Tissue kit (Qiagen) as previously described [24]. In the experiments shown in Fig 3, genomic DNA was extracted from the splenic MNCs of NOG-hCD34 mice in the same procedure. Genotyping PCR of A3H was performed using PfuUltra High Fidelity DNA polymerase (Agilent) according to the manufacturer’s protocol, and the following primers were used: Exon2_Fwd, 5’-GAA ACA CGA TGG CTC TGT TAA CAG CC-3’; Exon2_Rvrd, 5’-CTG CAC TGT TAA CAG CC TGA ACG GCT G-3’.
Exon3_Rev, 5’-CGG GGG TTT GCA CTC TTA T-3’; Exon4_Fwd, 5’-AGG AAG GAA GGA TTG TGG CTC A-3’; Exon4_Rev, 5’-GAG TCC TCA TGC TCA GCA CA-3’ (see also Fig 1A). For genotyping PCR of A3F, the following primers were used: A3F_exon5_8822_Fwd, 5’-GGT CTC TGC ATT GGG GTT TC-3’; A3F_exon5_9069_Rev: 5’-TGC ATT CCT AGC TGC TTA GC-3’. The resulting DNA fragments were directly sequenced, and, if needed, were cloned using a zero blunt TOPO PCR cloning kit (Thermo Fisher Scientific). The sequence was analyzed with Sequencher v5.1 software (Gene Codes Corporation).

Flow cytometry, hematology and cell sorting
Flow cytometry was performed with FACS Calibur (BD Biosciences) and FACSJazz (BD Biosciences) as previously described [11,12,22–24], and the obtained data were analysed with Cell Quest software (BD Biosciences) and FlowJo software (Tree Star, Inc.). For flow cytometry analysis, anti-CD45-PE (HI30; Biolegend), anti-CD3-APC-Cy7 (HIT3a; Biolegend), anti-CD4-APC (RPA-T4; Biolegend), anti-CD25-APC (BC96; eBioscience), and anti-Ki67-PE (B56; BD Biosciences) antibodies were used. Hematology was performed with a Celltac α MEK-6450 (Nihon Kohden Co.) as previously described [11,12,23,24,49]. Live cell sorting was performed using FACSJazz (BD Biosciences) according to the manufacture’s procedure. The purity of each population was >94% (see also S7 Fig).

Transfection, TZM-bl assay and Western blotting
Transfection, the TZM-bl assay and Western blotting were performed as previously described [11,12,23,24]. Briefly, in the experiments shown in Fig 1B & S3 Fig, HEK293 cells were cotransfected with an expression plasmid for flag-tagged A3H-II (0, 25, 50 and 100 ng) and the indicated IMCs (1 μg). In the experiments shown in Figs 1F, 1G, 3D & 3E, HEK293 cells were co-cotransfected with an expression plasmid for flag-tagged A3H-II (10 ng), pNLCSFV3Δvif (500 ng) and an expression plasmid for the indicated Vif tagged with HA (500 ng). In the experiments shown in Fig 5C, HEK293 cells were cotransfected with an expression plasmid for flag-tagged A3H-II (50 ng) and the indicated IMCs (1 μg). In the experiments shown in S1 Fig, HEK293 cells were cotransfected with an expression plasmid for flag-tagged A3D (50 ng), A3F (10 ng) or A3G (10 ng), pNLCSFV3Δvif (500 ng) and an expression plasmid for the indicated Vif tagged with HA (500 ng). For Western blotting, anti-Flag antibody (M2; Sigma), anti-HA antibody (3F10; Roche), anti-p24 antiserum (ViroStat), and anti-α-tubulin (TUBA) antibody (DM1A; Sigma) were used.

RT-PCR for vif cloning
RT-PCR was performed as previously described [24]. Briefly, viral RNA was extracted from the plasma of infected mice at 6 wpi using a QIAamp viral RNA mini kit (Qiagen), and cDNA was prepared as previously described [24]. RT-PCR was performed using PrimeSTAR GXL DNA polymerase according to the manufacturer’s protocol, and the following primers used are given: Vif-Fwd, 5’-GGT TGG AAA GGA CCA GCA AA-3’; Vif-Rev, 5’-GCC CAA GTA TCC CCG TAA GT-3’. The resulting DNA fragments were cloned using a zero blunt TOPO PCR cloning kit (Thermo Fisher Scientific), and the sequence was analyzed with Sequencher v5.1 software (Gene Codes Corporation).

Molecular phylogenetic
The vif ORF sequences (Figs 1E, 2C & 3C) were aligned by using MUSCLE [54] implemented in MEGA 6 software [55]. ML phylogenetic trees were constructed using MEGA 5.1 software.
The Vif sequences (Fig 5A and 5B & S10 Table; one sequence per patient) were extracted from Los Alamos National Laboratory HIV-1 sequence database (https://www.hiv.lanl.gov/components/sequence/HIV/search/search.html). These sequences were aligned and the phylogenetic tree was constructed as described above.

Plasmid construction

A series of HA-tagged Vif expression plasmids are based on pDON-AI (Takara) and are constructed in our previous study [24]. To prepare the expression plasmids of Vif derivatives (Figs 1F, 1G, 3D & 3E), the pCRII-blunt-TOPO containing vif ORFs were digested with EcoRI and blunted. The resultant DNA fragments containing vif ORF were subcloned into the HpaI site of pDON-AI (Takara).

RNA-seq and data mining

Human MNCs were isolated from the spleen of humanized mice as described above and RNA was extracted using QIAamp RNA Blood Mini kit (Qiagen) as described above [11,23,24]. RNA-seq analysis was conducted in Medical & Biological Laboratories, co (Nagoya, Japan). The obtained raw sequence data (.fastq files) were mapped to the human reference genome (NCBI hg19) by Bowtie2 version 2.2.5 [56], followed by spliced junction detection by Tophat2 version 2.1.0 [57]. Several R (versions 3.1.1) and Bioconductor packages were used to further process the gene expression data. Read count data for each sample were extracted by package 'Rsubread' [58]. The obtained raw read count data were then normalized by applying repeated edgeR normalization defined in package 'TCC' [59]. The normalized read count data were classified into two groups according to infection status (HIV-1 infected, or uninfected as control). The expression data were analyzed to detect differentially expression genes by package edgeR [60]. Top-ranked genes were selected as differentially expressed genes (DEGs) with the following threshold values: False Discovery Rate (FDR) less than 0.001 calculated by the Benjamini-Hochberg method [61], and more than twice up-regulated or less than half down-regulated normalized gene expressions compared with the control (see Fig 4B & S8 Table). DEGs were then used to obtain enriched biological functions by a parametric gene set enrichment analysis by using package ‘gage’ [62]. The method defined in ‘gage’ enabled to extract gene ontology terms associated with up-regulated DEGs. Finally, a distance matrix was calculated from the expression data for DEGs based on the correlation distance [63], and the distance matrix was converted by the Z-transformation defined in package ‘gplots’ to visualize the result with a heatmap (Fig 4A).

Real-time RT-PCR

Real-time RT-PCR was performed as previously described [20,24] using CFX connect real-time system (Biorad) and the following primers: A3H-Fwd (RSH2757), 5' AGC TGT GGC CAG AAG CAC-3' and A3H-Rev (RSH2758), 5' CGG AAT GTT TCG GCT GTT-3'. A3D, A3F, A3G were amplified by using the primers reported previously [32], and the primers for GAPDH were purchased from Thermo Fisher Scientific.

Database analysis

The information of A3H haplotypes of individuals was extracted from the 1000 Genomes Project (http://www.internationalgenome.org) [36]. We obtained the Phase 1 VCF (variant call format) data of 1092 individuals from all available human populations. From this phased variant
dataset we extracted the information of 5 A3H SNPs 15, 18, 105, 121, and 178 and estimated the frequencies of A3H haplotypes for each population.

**Mathematical modeling and simulations**

The following simple model describes the HIV-1 transmission among human population:

\[
\frac{dS(t)}{dt} = b - dS(t) - \frac{\beta S(t)I(t)}{N(t)}, \quad \frac{dI(t)}{dt} = \frac{\beta S(t)I(t)}{N(t)} - \mu I(t),
\]

where \(S(t)\) and \(I(t)\) represent the number of susceptible and infected individuals, respectively \([64]\). \(N(t)\) is the total population size at time \(t\), and \(N(0) = b/d\) is the initial size. Susceptible individuals are born at rate \(b\) and removed at rate \(d\), and infected individuals transmit HIV-1 at a rate \(\beta\) during their infectious period of \(1/\mu\). To describe the dissemination of hyper HIV-1 in the human population, we modified the above model as follows:

\[
\frac{dS^S(t)}{dt} = b_S - dS^S(t) - \frac{\beta S^S(t)I(t)}{N(t)} \{I^H(t) + I^L(t) + I^F(t) + I^P(t)\},
\]

\[
\frac{dI^H(t)}{dt} = \frac{\beta S^S(t)}{N(t)} \{I^H(t) + I^L(t)\} - \mu I^H(t),
\]

\[
\frac{dI^L(t)}{dt} = \frac{\beta S^S(t)}{N(t)} \{I^H(t) + I^L(t)\} - \mu I^L(t),
\]

\[
\frac{dS^S(t)}{dt} = b_S - dS^S(t) - \frac{\beta S^S(t)I(t)}{N(t)} \{I^H(t) + I^L(t) + I^F(t) + I^P(t)\},
\]

\[
\frac{dI^L(t)}{dt} = \frac{\beta S^S(t)}{N(t)} \{I^H(t) + I^L(t) + fI^F(t)\} - \mu I^L(t),
\]

\[
\frac{dI^P(t)}{dt} = \frac{\beta S^S(t)}{N(t)} \{I^H(t) + (1-f)I^F(t)\} - \mu I^P(t).
\]

The variable \(S^S(t)\) is the number of susceptible individuals harboring unstable A3H haplotype, and \(I^H(t)\) and \(I^L(t)\) are the number of infected individuals with hyper and hypo HIV-1s, respectively. On the other hand, the variable \(S^S(t)\) is the number of susceptible individuals harboring stable A3H haplotype, and \(I^F(t)\) and \(I^P(t)\) are the number of infected individuals with hyper and hypo HIV-1s, respectively. We assumed that the susceptible individuals harboring unstable and stable A3H haplotype are born at the rates \(b_U\) and \(b_S = b - b_U\), respectively. Furthermore, we considered that the fraction, \(f\), of newly infected individuals harboring stable A3H haplotype with hypo HIV-1 become infected individuals with hyper HIV-1 because of adaptive evolution of hyper HIV-1 from hypo HIV-1 in vivo, as we observed in the stable A3H mice infected with NLCFSFV3 (Fig 3 & S6 Table).

To investigate how the frequency of hyper HIV-1 at 100 years after the initial infection (i.e., \((I^H(100) + I^L(100))/(I^H(100) + I^F(100) + I^P(100) + I^F(100))\)) is determined depend on the proportion of the people harboring stable A3H haplotype (i.e., \(S^S(0)/N(0) = \frac{b_S}{d}/\frac{b}{d} = b/\mu\)) we simulated the transmission dynamics of hyper and hypo HIV-1s among 1 million individuals for \(0 < b/\mu \leq 1\) based on the above modified mathematical model. Here we simply fixed \(1/d = 35\) years (i.e., adults aged 15–49 years), which implies \(b = dN(0) = 2.86 \times 10^4\) per year. As
previously estimated in [65,66], we assumed that $\beta = 4.53$ per year, and $1/\mu = 35$ years corresponding to HIV-1-infected individuals with the mean set-point viral load of $3.2 \times 10^4$ RNA copies/ml. The fraction, $f$, is fixed to be 0.60 in our simulations based on our findings in the stable A3H humanized mice infected with NLCSFV3 (Fig 3 & S6 Table). Our simulations well reproduced that the prevalence of hyper HIV-1 in the human population with different stable A3H proportion (Fig 5E).

Statistics

The data are presented as averages ± SDs or SEMs. Statistically significant differences were determined by Student’s $t$ test, Paired $t$ test, and Mann-Whitney U test. To determine statistically significant correlations (S9 Fig), the Spearman rank correlation test was applied to the data.

Accession number

An accession number for the data generated in this study is as follows: the RNA-seq data of the splenic MNCs of HIV-1-infected (n = 4) and mock-infected (n = 4) humanized mice (GEO: GSE92262).

Supporting information

S1 Fig. Evaluation of anti-A3 activity of Vif derivatives detected in infected humanized mice. The expression plasmids of the Vif derivatives were cotransfected with pNLCSFV3Δvif and either with or without expression plasmids for Flag-tagged A3D (50 ng), A3F (10 ng) or A3G (10 ng) into HEK293T cells. The infectivity of released virions was determined by using TZM-bl cells. *$P < 0.05$ versus "no A3/no Vif" by Student’s $t$ test. The assay was performed in triplicate. The data represents average with SD. NS, no statistic difference versus "no A3/no Vif". The symbols are identical to those in Fig 1E.

(TIF)

S2 Fig. Real-time RT-PCR of A3D, A3F and A3G. (A) Splenic human CD4$^+$ T cells (CD45$^+$ CD3$^+$ CD8$^-$ cells) of mock-infected mice (n = 7) and HIV-1-infected mice (n = 13) were sorted using FACSJazz and the mRNA expression levels of A3D, A3F and A3G were analyzed by real-time RT-PCR as described in Materials and Methods. The value of mock-infected mice is set as 1. *$P < 0.05$ versus mock-infected mice by Mann-Whitney U test. (B) The mRNA expression levels of A3D, A3F and A3G in infected mice expressing intermediate A3H (n = 7) and stable A3H (n = 6) were analyzed by real-time RT-PCR. NS, no statistic difference. AU, arbitrary unit.

(TIF)

S3 Fig. Sensitivity of the 3 IMCs to A3H-II. The IMCs (strains NLCSFV3, JRCSF, AD8, vif-deleted NLCSFV3, hyper NLCSFV3 and hypo NLCSFV3) were cotransfected either with Flag-tagged A3H-II expression plasmid at 4 different amounts (0, 25, 50, and 100 ng) into HEK293T cells. The assay was performed in triplicate. The infectivity of released virus was determined by using TZM-bl cells, and the percentage of the value of "no A3H-II" is shown. The data represents average with SD. The horizontal broken line represents 100%. Note that various versions of NLCSFV3 differ only in $vif$.

(TIF)

S4 Fig. Viral $vif$ sequences in the infected mice with stable A3H. The $vif$ ORF of viral RNA in the plasma of infected mice (Fig 3C) were analyzed. Raw data (A) and mutation matrix
(B) are respectively shown. (TIF)

**S5 Fig. Viral vif sequences in the infected mice with intermediate A3H.** (A) Phylogenetic trees of vif sequence. Viral vif sequences in the plasma of infected mice at 6 wpi were analyzed as described in Materials and Methods. Results of 3 infected mice with intermediate A3H (mice #50–52) are respectively shown. Scale bar represents one nucleotide substitution. Raw data (B) and mutation matrix (C) are also shown. (TIF)

**S6 Fig. Up-regulation of A3H expression by activation stimuli.** (A, B) Activation and up-regulation of A3H expression in in vitro human CD4+ T cell culture. (A) Human peripheral CD4+ T cells (n = 5) were stimulated with anti-CD3/anti-CD28 dynabeads as previously described [23], and the activation status was analyzed by staining with CD25. Representative dot plots of flow cytometry (left) and the summarized results (right) are shown. (B) The mRNA expression level of A3H in the human peripheral CD4+ T cells with or without stimulation of anti-CD3/anti-CD28 dynabeads (n = 5 each) was analyzed by real-time RT-PCR as described in Materials and Methods. The average value of non-stimulated CD4+ T cells is set as 1. Paired t test was applied to determine statistically significant difference. (C) Activation status of the human CD4+ T cells of humanized mice. Splenic human CD4+ T cells of humanized mice (n = 10) and the human peripheral CD4+ T cells with or without stimulation of anti-CD3/anti-CD28 dynabeads (n = 5 each) were stained with intracellular Ki67, an activation marker, and its expression level was analyzed by flow cytometry. Representative dot plots of flow cytometry (left) and the summarized results (right) are shown. In panels A and C, horizontal bars represent averages with SEMs. The numbers on each dot plot indicates the percentage of gated cells. (TIF)

**S7 Fig. Representative of live cell sorting.** Representative dot plots for cell sorting are shown. The numbers on each dot plot indicates the percentage of gated cells. (TIF)

**S8 Fig. Conservation of the Vif responsible residues to counteract stable A3H.** The Vif ORF sequences of HIV-1 group M (n = 2,976; one sequence per patient) were extracted from the database and aligned as described in Materials and Methods. The logoplot of Vif amino acid sequence is constructed using WebLogo 3 (http://weblogo.threeplusone.com) and the residues at positions 25–55 are shown. The two amino acids responsible for stable A3H counteraction (residues 39 and 48) are indicated in red. As a control, the YRHHY motif (residues 40–44) that is responsible for A3G counteraction is indicated in blue. (TIF)

**S9 Fig. Correlation between the percentages of hyper HIV-1 and stable A3H individuals in the world.** The percentage of hyper Vif (y-axis) and the proportion of stable A3H individuals (x-axis) in each region and country are respectively extracted from the database. To determine statistically significant correlations, the Spearman rank correlation test was applied to the data. See also S6 & S7 Tables. (TIF)

**S10 Fig. No Vif reversion in the humanized mice infected with 4A HIV-1.** Phylogenetic trees of vif sequence. Viral vif sequences in the plasma of humanized mice infected wit 4A HIV-1, which is incapable of counteracting A3F, at 6 wpi were analyzed as described in Materials and Methods. Results of 2 infected mice with intermediate A3H (mice #65 and #66) are respectively shown. The wild-type NLCSFV3 vif sequence was used as the outgroup. Scale bar
represents one nucleotide substitution.

(TIF)

S1 Table. Humanized mice used in Figs 1 & 2. A full list of the 14 humanized mice used in Figs 1 & 2.

(PDF)

S2 Table. Percentage of hyper Vif derivatives in stable A3H humanized mice co-inoculated with hyper and hypo HIV-1s. A full list of the percentages of hyper Vif derivatives in the 8 stable A3H humanized mice (Fig 1).

(PDF)

S3 Table. Summary of the sequences of hypo Vif derivatives detected in intermediate A3H humanized mice co-inoculated with hyper and hypo HIV-1s. A full list of hypo vif derivatives in the 6 intermediate A3H humanized mice.

(PDF)

S4 Table. Percentage of hyper Vif derivatives in intermediate A3H humanized mice co-inoculated with hyper and hypo HIV-1s. A full list of the percentages of hyper Vif derivatives in the 6 intermediate A3H humanized mice (Fig 2).

(PDF)

S5 Table. Humanized mice used in Fig 3 & S10 Fig. A full list of the 52 humanized mice used in Fig 3 & S10 Fig.

(PDF)

S6 Table. Percentage of hyper Vif derivatives in stable A3H humanized mice infected with HIV-1 NLCSFV3. A full list of the percentages of hyper Vif derivatives in the 4 stable A3H humanized mice (Fig 3).

(PDF)

S7 Table. Percentage of hyper Vif derivatives in intermediate A3H humanized mice infected with HIV-1 NLCSFV3. A full list of the percentages of hyper Vif derivatives in the 3 intermediate A3H humanized mice (S5 Fig).

(PDF)

S8 Table. Top 50 annotations of GSEA analysis. A full list of the top 50 annotations of GSEA analysis.

(PDF)

S9 Table. Amino acid residues positioned at 39 and 48 of the 24 IMCs used in this study. A full list of the amino acid residues positioned at 39 and 48 of the 24 IMCs used in this study.

(PDF)

S10 Table. Percentage of hyper Vif in HIV-1 subtypes and groups deposited in HIV-1 sequence database. A full list of the percentages of hyper Vif in HIV-1 subtypes and groups deposited in Los Alamos National Laboratory HIV-1 sequence database (https://www.hiv.lanl.gov/components/sequence/HIV/search/search.html).

(PDF)

S11 Table. Proportion of stable A3H individuals in each population and region. A full list of the proportion of stable A3H individuals in each population and region from 1000 Genomes Project (http://www.internationalgenome.org).

(PDF)
S12 Table. Proportions of hyper HIV-1 and stable A3H individuals in each region and country. A full list of the proportions of hyper HIV-1 and stable A3H individuals in each region and country.

Acknowledgments

We would like to thank Drs. Beatrice H. Hahn, Frederic Bibollet-Ruche, and Nicholas F. Par- rish (University of Pennsylvania, USA) and Drs. Frank Kirchhoff and Daniel Sauter (Ulm University Medical Center, Germany) for providing materials, Dr. Osamu Ohara (RIKEN Yokohama Institute, Japan) for technical assistance of RNA-seq analyses, and Dr. Terumasa Ikeda (University of Minnesota, USA) for crucial suggestions, and Dr. Dong Sung An (University of California, Los Angeles, USA) for providing human CD34+ hematopoietic stem cells. We also thank Ms. Kotubu Misawa for her dedicated support.

Author Contributions

Conceptualization: KS.
Data curation: SN DE.
Formal analysis: SN TF YT SI.
Funding acquisition: RSH YK KS.
Investigation: YN NM GJF MM EY AS RY KS.
Methodology: NM.
Supervision: RSH YK KS.
Validation: YN NM GJF MM EY AS RY KS.
Visualization: KS.
Writing – original draft: KS.
Writing – review & editing: YN GJF SN DE SI RSH YK KS.

References

1. LaRue RS, Andresdottir V, Blanchard Y, Conticello SG, Derse D, et al. (2009) Guidelines for naming nonprimate APOBEC3 genes and proteins. J Virol 83: 494–497. https://doi.org/10.1128/JVI.01976-08 PMID: 18987154
2. Harris RS, Dudley JP (2015) APOBECs and virus restriction. Virology 479–480: 131–145. https://doi.org/10.1016/j.virol.2015.03.012 PMID: 25818029
3. Zhang J (2003) Evolution by gene duplication: an update. Trends Ecol Evol 18: 292–298.
4. Sawyer SL, Emerman M, Malik HS (2004) Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G. PLOS Biol 2: E275. https://doi.org/10.1371/journal.pbio.0020275 PMID: 15269786
5. Sheehy AM, Gaddis NC, Choi JD, Malim MH (2002) Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418: 646–650. PMID: 12167863
6. Harris RS, Liddament MT (2004) Retroviral restriction by APOBEC proteins. Nat Rev Immunol 4: 868–877. https://doi.org/10.1038/nri1489 PMID: 15516966
7. Malim MH (2009) APOBEC proteins and intrinsic resistance to HIV-1 Infection. Philos Trans R Soc Lond B Biol Sci 364: 675–687. https://doi.org/10.1098/rstb.2008.0185 PMID: 19038776
8. Malim MH, Emerman M (2008) HIV-1 accessory proteins—ensuring viral survival in a hostile environment. Cell Host Microbe 3: 388–398. https://doi.org/10.1016/j.chom.2008.04.008 PMID: 18541215
9. Krisko JF, Begum N, Baker CE, Foster JL, Garcia JV (2016) APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication. J Virol 90: 4681–4695. https://doi.org/10.1128/JVI.03275-15 PMID: 26912618

10. Krisko JF, Martinez-Torres F, Foster JL, Garcia JV (2013) HIV Restriction by APOBEC3 in Humanized Mice. PLOS Pathog 9: e1003242. https://doi.org/10.1371/journal.ppat.1003242 PMID: 23555255

11. Sato K, Izumi T, Misawa N, Kobayashi T, Yamashita Y, et al. (2010) Remarkable lethal G-to-A mutations in vif-proficient HIV-1 virus by individual APOBEC3 proteins in humanized mice. J Virol 84: 9546–9556. https://doi.org/10.1128/JVI.00823-10 PMID: 20610708

12. Sato K, Misawa N, Iwami S, Satou Y, Matsuoka M, et al. (2013) HIV-1 Vpr accelerates viral replication during acute infection by exploitation of proliferating CD4+ T cells in vivo. PLOS Pathog 9: e1003812. https://doi.org/10.1371/journal.ppat.1003812 PMID: 24339781

13. Simon V, Bloch N, Landau NR (2015) Intrinsic host restrictions to HIV-1 and mechanisms of viral escape. Nat Immunol 16: 546–553. https://doi.org/10.1038/ni.3156 PMID: 25988868

14. OhAinle M, Kerns JA, Li MM, Malik HS, Emerman M (2008) Antiretroviral activity of APOBEC3H was lost twice in recent human evolution. Cell Host Microbe 4: 249–259. https://doi.org/10.1016/j.chom.2008.07.005 PMID: 18945781

15. Wang X, Abudu A, Son S, Dang Y, Venta PJ, et al. (2011) Analysis of human APOBEC3H haplotypes and anti-human immunodeficiency virus type 1 activity. J Virol 85: 3142–3152. https://doi.org/10.1128/JVI.00823-10 PMID: 21270145

16. Harari A, Ooms M, Mulder LC, Simon V (2009) Polymorphisms and splice variants influence the antiretroviral activity of human APOBEC3H. J Virol 83: 295–303. https://doi.org/10.1128/JVI.02049-10 PMID: 18945781

17. Starrett GJ, Luengas EM, McCann JL, Ebrahimi D, Temiz NA, et al. (2016) The DNA cytosine deaminase APOBEC3H haplotype I likely contributes to breast and lung cancer mutagenesis. Nat Commun 7: 12918. https://doi.org/10.1038/ncomms12918 PMID: 27650891

18. Ooms M, Brayton B, Letko M, Maio SM, Pilcher CD, et al. (2013) HIV-1 Vif adaptation to human APOBEC3H haplotypes. Cell Host Microbe 14: 411–421. https://doi.org/10.1016/j.chom.2013.09.006 PMID: 24139399

19. Ooms M, Letko M, Binka M, Simon V (2013) The resistance of human APOBEC3H to HIV-1 NL4-3 molecular clone is determined by a single amino acid in Vif. PLOS One 8: e57744. https://doi.org/10.1371/journal.pone.0057744

20. Refsland EW, Hultquist JF, Luengas EM, Ikeda T, Shaban NM, et al. (2014) Natural polymorphisms in human APOBEC3H and HIV-1 Vif combine in primary T lymphocytes to affect viral G-to-A mutation levels and infectivity. PLOS Genet 10: e1004761. https://doi.org/10.1371/journal.pgen.1004761 PMID: 25411794

21. Suzuki Y, Koyanagi Y, Tanaka Y, Murakami T, Misawa N, et al. (1999) Determinant in human immunodeficiency virus type 1 for efficient replication under cytokine-induced CD4+ T-helper 1 (Th1)- and Th2-type conditions. J Virol 73: 316–324. PMID: 9847335

22. Nie C, Sato K, Misawa N, Kitayama H, Fujino H, et al. (2009) Selective infection of CD4+ effector memory T lymphocytes leads to preferential depletion of memory T lymphocytes in R5 HIV-1-infected humanized NOD/SCID/IL-2Rγnull mice. Virology 394: 64–72. https://doi.org/10.1016/j.virol.2009.08.011 PMID: 19744686

23. Sato K, Misawa N, Fukuhara M, Iwami S, An DS, et al. (2012) Vpu augments the initial burst phase of HIV-1 propagation and downregulates BST2 and CD4 in humanized mice. J Virol 86: 5000–5013. https://doi.org/10.1128/JVI.07062-11 PMID: 22357275

24. Sato K, Takeuchi JS, Misawa N, Izumi T, Kobayashi T, et al. (2014) APOBEC3D and APOBEC3F potently promote HIV-1 diversification and evolution in humanized mouse model. PLOS Pathog 10: e1004453. https://doi.org/10.1371/journal.ppat.1004453 PMID: 25330146

25. Hultquist JF, Lengyel JA, Refsland EW, LaRue RS, Lackey L, et al. (2011) Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J Virol 85: 11220–11234. https://doi.org/10.1128/JVI.05238-11 PMID: 21835787

26. Bizinoto MC, Leal E, Diaz RS, Janini LM (2011) Loci polymorphisms of the APOBEC3G gene in HIV type 1-infected Brazilians. AIDS Res Hum Retroviruses 27: 137–141. https://doi.org/10.1089/aid.2010.0146 PMID: 20874421

27. Reddy K, Winkler CA, Werner L, Milisana K, Abdool Karim SS, et al. (2010) APOBEC3G expression is dysregulated in primary HIV-1 infection and polymorphic variants influence CD4+ T-cell counts and plasma viral load. AIDS 24: 195–204. https://doi.org/10.1097/QAD.0b019e3283353bba PMID: 19996938
28. An P, Bleiber G, Duggal P, Nelson G, May M, et al. (2004) APOBEC3G genetic variants and their influence on the progression to AIDS. J Virol 78: 11070–11076. https://doi.org/10.1128/JVI.78.20.11070-11076.2004 PMID: 15452227

29. Mulder LC, Ooms M, Majdak S, Smetsesman J, Linscheid C, et al. (2010) Moderate influence of human APOBEC3F on HIV-1 replication in primary lymphocytes. J Virol 84: 9613–9617. https://doi.org/10.1128/JVI.02630-09 PMID: 20592068

30. An P, Penugonda S, Thorball CW, Bartha I, Goedert JJ, et al. (2016) Role of APOBEC3F Gene Variation in HIV-1 Disease Progression and Pneumocystis Pneumonia. PLOS Genet 12: e1005921. https://doi.org/10.1371/journal.pgen.1005921 PMID: 26942578

31. Duggal NK, Fu W, Akey JM, Emerman M (2013) Identification and antiviral activity of common polymorphisms in the APOBEC3 locus in human populations. Virology 443: 329–337. https://doi.org/10.1016/j.virol.2013.05.016 PMID: 23755966

32. Refsland EW, Stenglein MD, Shindo K, Albin JS, Brown WL, et al. (2010) Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res 38: 4274–4284. https://doi.org/10.1093/nar/gkq174 PMID: 20308164

33. Vatakis DN, Bristol G, Wilkinson TA, Chow SA, Zack JA (2007) Immediate activation fails to rescue efficient human immunodeficiency virus replication in quiescent CD4+ T cells. J Virol 81: 3574–3582. https://doi.org/10.1128/JVI.02569-06 PMID: 17229711

34. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, et al. (2006) Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 12: 1365–1371. https://doi.org/10.1038/nature11632 PMID: 17115046

35. Emilie D, Peuchmaur M, Maillot MC, Crevon MC, Brousse N, et al. (1990) Production of interleukins in human immunodeficiency virus-1-replicating lymph nodes. J Clin Invest 86: 148–159. https://doi.org/10.1172/JCI114678 PMID: 2114424

36. Genomes Project C, Abecasis GR, Auton A, Brooks LD, DePristo MA, et al. (2012) An integrated map of genetic variation from 1,092 human genomes. Nature 491: 56–65. https://doi.org/10.1038/nature11632 PMID: 23128226

37. Russell RA, Smith J, Barr R, Bhattacharyya D, Pathak VK (2009) Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif. J Virol 83: 1992–2003. https://doi.org/10.1128/JVI.01621-08 PMID: 19036809

38. Chaipan C, Smith JL, Hu WS, Pathak VK (2013) APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages. J Virol 87: 444–453. https://doi.org/10.1128/JVI.00676-12 PMID: 23097438

39. Russell RA, Pathak VK (2007) Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J Virol 81: 8201–8210. https://doi.org/10.1128/JVI.00395-07 PMID: 17522216

40. Siliciano JD, Siliciano RF (2013) Recent trends in HIV-1 drug resistance. Curr Opin Virol 3: 487–494. https://doi.org/10.1016/j.coviro.2013.08.007 PMID: 24021560

41. Pingen M, Nijhuis M, de Bruijn JA, Boucher CA, Wensing AM (2011) Evolutionary pathways of transmitted drug-resistant HIV-1. J Antimicrob Chemother 66: 1467–1480. https://doi.org/10.1093/jac/dkr157 PMID: 21502281

42. Albin JS, Hache G, Hultquist JF, Brown WL, Harris RS (2010) Long-term restriction by APOBEC3F selects human immunodeficiency virus type 1 variants with restored Vif function. J Virol 84: 10209–10219. https://doi.org/10.1128/JVI.00632-10 PMID: 20686027

43. Hache G, Shindo K, Albin JS, Harris RS (2008) Evolution of HIV-1 isolates that use a novel Vif-independent mechanism to resist restriction by human APOBEC3F. J Virol 82: 8201–8210. https://doi.org/10.1128/JVI.00395-07 PMID: 17522216

44. Anderson RM, May RM (1990) Immunisation and herd immunity. Lancet 335: 641–645. PMID: 1969023

45. Rashid H, Khandaker G, Booy R (2012) Vaccination and herd immunity: what more do we know? Curr Opin Infect Dis 25: 243–249. https://doi.org/10.1097/QCO.0b013e32835f727f PMID: 22561998

46. Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, et al. (2002) NOD/SCID/γcnull mouse: an excellent recipient mouse model for engraftment of human cells. Blood 100: 3175–3182. https://doi.org/10.1182/blood-2001-12-0207 PMID: 12384415

47. An DS, Poon B, Ho Tsong Fang R, Weijer K, Blom B, et al. (2007) Use of a novel chimeric mouse model with a functionally active human immune system to study human immunodeficiency virus type 1 infection. Clin Vaccine Immunol 14: 391–396. https://doi.org/10.1128/CVI.00403-06 PMID: 17314230

48. Sato K, Koyanagi Y (2011) The mouse is out of the bag: insights and perspectives on HIV-1-infected humanized mouse models. Exp Biol Med 236: 977–985.
49. Sato K, Misawa N, Nie C, Satou Y, Iwakiri D, et al. (2011) A novel animal model of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in humanized mice. Blood 117: 5663–5673. https://doi.org/10.1182/blood-2010-09-305979 PMID: 21467545

50. Sato K, Nie C, Misawa N, Tanaka Y, Ito M, et al. (2010) Dynamics of memory and naive CD8+ T lymphocytes in humanized NOD/SCID/IL-2Rγnull mice infected with CCR5-tropic HIV-1. Vaccine 28: B32–37. https://doi.org/10.1016/j.vaccine.2009.10.154 PMID: 20510741

51. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, et al. (2002) Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46: 1896–1905. https://doi.org/10.1128/AAC.46.6.1896-1905.2002 PMID: 12019106

52. Koyanagi Y, Miles S, Mitsuyasu RT, Merrill JE, Vinters HV, et al. (1987) Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science 236: 819–822. PMID: 3646751

53. Theodore TS, Englund G, Buckler-White A, Buckler CE, Martin MA, et al. (1996) Construction and characterization of a stable full-length macrophage-tropic HIV type 1 molecular clone that directs the production of high titers of progeny virions. AIDS Res Hum Retroviruses 12: 191–194. https://doi.org/10.1089/aid.1996.12.191 PMID: 8835195

54. Edgar RC (2004) MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res 32: 1792–1797. https://doi.org/10.1093/nar/gkh340 PMID: 15034147

55. Tamura K, Stecher G, Peterson D, Filipski A, Kumar S (2013) MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. Mol Biol Evol 30: 2725–2729. https://doi.org/10.1093/molbev/mst197 PMID: 24132122

56. Langmead B, Salzberg SL (2012) Fast gapped-read alignment with Bowtie 2. Nat Methods 9: 357–359. https://doi.org/10.1038/nmeth.1923 PMID: 22388286

57. Trapnell C, Pachter L, Salzberg SL (2009) TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25: 1105–1111. https://doi.org/10.1093/bioinformatics/btp120 PMID: 19289445

58. Liao Y, Smyth GK, Shi W (2013) The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote. Nucleic Acids Res 41: e108. https://doi.org/10.1093/nar/gkt214 PMID: 23558742

59. Sun J, Nishiyama T, Shimizu K, Kadota K (2013) TCC: an R package for comparing tag count data with robust normalization strategies. BMC Bioinformatics 14: 219. https://doi.org/10.1186/1471-2105-14-219 PMID: 23837715

60. Robinson MD, McCarthy DJ, Smyth GK (2010) edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26: 139–140. https://doi.org/10.1093/bioinformatics/btp126 PMID: 19910308

61. Benjamin Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the royal statistical society Series B (Methodological) 57: 289–300.

62. Luo W, Friedman MS, Sheddten K, Hankenson KD, Woolf PJ (2009) GAGE: generally applicable gene set enrichment for pathway analysis. BMC Bioinformatics 10: 161. https://doi.org/10.1186/1471-2105-10-161 PMID: 19473525

63. Eisen MB, Spellman PT, Brown PO, Botstein D (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 95: 14863–14868. PMID: 9843981

64. Vynnycky E, White RG, Fine PEM (2010) An Introduction to Infectious Disease Modelling. Oxford, UK: Oxford University Press.

65. Fraser C, Hollingsworth TD, Chapman R, de Wolf F, Hanage WP (2007) Variation in HIV-1 set-point viral load: epidemiological analysis and an evolutionary hypothesis. Proc Natl Acad Sci U S A 104: 17441–17446. https://doi.org/10.1073/pnas.0708559104 PMID: 17954909

66. Iwami S, Sato K, Morita S, Inaba H, Kobayashi T, et al. (2015) Pandemic HIV-1 Vpu overcomes intrinsic herd immunity mediated by tetherin. Sci Rep 5: 12256. https://doi.org/10.1038/srep12256 PMID: 26194634